Company Overview
Plus Therapeutics, Inc. operates as a clinical-stage pharmaceutical company dedicated to the development, manufacture, and commercialization of therapeutic treatments specifically designed for patients suffering from cancer. The firm functions within the healthcare sector and the biotechnology industry, positioning itself to address unmet medical needs through the creation of novel radiotherapeutic solutions. The company maintains a market capitalization of $41.03M and employs a workforce of 28 individuals to support its research and development objectives. These financial metrics indicate that Plus Therapeutics is a small-cap entity with limited revenue generation relative to its peers, reflecting the typical capital-intensive nature of early-stage biotechnology firms that prioritize product development over immediate profitability. The specific focus on its lead radiotherapeutic candidate, rhenium obisbemeda, underscores a strategic specialization in treating central nervous system conditions, distinguishing its product pipeline from broader oncology competitors.
Financial Health
Plus Therapeutics reported revenue of $5.21M over the trailing twelve months, while simultaneously reporting a net income of $-22,386,000 and an EBITDA of $-14,853,000. The substantial disparity between the $5.21M in revenue and the $-22,386,000 in net income reveals a highly leveraged cost structure where operating expenses significantly exceed all income streams, a common characteristic of clinical-stage companies burning cash on research. The company generated free cash flow of $-13,597,750, indicating that it is currently consuming its cash reserves rather than generating liquidity, which limits immediate financial flexibility without external capital raises. Analysis of the three reported margins shows a gross margin of -60.7%, an operating margin of -420.0%, and a profit margin of 0.0%, all of which indicate severe operational inefficiencies typical of entities that have not yet achieved commercial product sales. On the balance sheet, the company holds $8.61M in cash against $821,000 in debt, supported by a debt-to-equity ratio of 20.55, suggesting a capital structure that is heavily weighted toward equity financing rather than traditional debt leverage. The current ratio stands at 1.23, which indicates that the company possesses sufficient current assets to cover its short-term liabilities, providing a baseline level of short-term liquidity despite the negative operating performance. Furthermore, the return on equity is listed as N/A, while the return on assets is -83.3%, metrics that collectively reveal that management has not yet generated positive returns on the capital deployed into the business, highlighting the early-stage risks inherent in the biotechnology sector.
Valuation Assessment
The valuation metrics for Plus Therapeutics show a P/E ratio (TTM) of N/A and a forward P/E of -2.56, implying that the market is not currently pricing the stock based on trailing earnings due to the company's losses, but rather anticipating a future earnings trajectory that has not yet materialized. The price-to-book ratio is 7.93, which indicates that the market is valuing the company at a significant premium over its book value, reflecting high expectations for the potential success of its radiotherapeutic pipeline despite current financial deficits. Alternative valuation metrics such as a price-to-sales ratio of 7.87 and an EV/EBITDA of -2.13 suggest that investors are focusing on revenue potential and enterprise value relative to earnings power, rather than traditional profitability multiples. The stock trades between a 52-week high of $1.77 and a 52-week low of $0.16, meaning the current price sits somewhere within this wide range, capturing high volatility often associated with speculative biotechnology stocks. The beta of 0.83 indicates that the stock's price volatility is slightly lower than the broader market, suggesting that while the asset is still sensitive to market movements, it may experience less extreme swings than high-beta technology or small-cap growth stocks.
Growth & Income
Plus Therapeutics recorded a revenue growth rate of -3.2% year-over-year, while earnings growth is listed as N/A, indicating that the company is currently contracting in revenue and has not yet established a positive earnings trajectory to measure against. Since the company reports no earnings growth and is operating at a loss, the concept of earnings growing faster or slower than revenue is currently abstract, but the negative revenue trend suggests a contraction in sales or a shift in market dynamics for its current offerings. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning that it does not distribute profits to shareholders and instead retains all available capital to fund its ongoing research and development efforts. This reinvestment strategy is standard for clinical-stage pharmaceutical companies, which prioritize funding their pipeline over providing income to shareholders. Overall, the growth and income profile of Plus Therapeutics is characterized by negative revenue momentum, a complete lack of dividend income, and a reliance on cash reserves to sustain operations while waiting for future commercialization milestones.